Stakeholder Insight: Adjunct Therapies in Breast Cancer

Introduction

This In-Depth Analysis provides insight into the attitudes about, and requirements for, supportive care. In particular, it quantifies the untapped market for bisphosphonates and, by determining the obstacles to the increased use of these agents, establishes routes to market expansion. 

Scope

The use of anti-emetics that treat the nausea and vomiting associated with cancer treatment is explored 

Datamonitor asks whether or not bisphosphonates would be accepted in the prevention of bone metastases 

The report examines whether HGFs are under-utilized in the treatment of anemic and neutropenic breast cancer patients 

Cancer analgesics (usually opioids) are used to alleviate the pain caused by surgery and growth of the tumor. Is cost a greater issue than efficacy? 

Report Highlights

An analysis of Datamonitor’s Breast Cancer Insight survey results, which interviewed 580 leading breast cancer specialists across Europe, the US and Japan, in 2002, provides insight into the attitudes about, and requirements for, supportive care. 

Reasons to Purchase

Plan new drug development to meet patient management requirements 

Explore the reasons, rational and emotional, behind cancer specialists' decisions 

Predict future trends and perception in the treatment of breast cancer patients 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a261